Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.

Détails

ID Serval
serval:BIB_07FF122177DB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
Périodique
European journal of gastroenterology & hepatology
Auteur(s)
Guilcher K., Fournier N., Schoepfer A., Schibli S., Spalinger J., Braegger C., Nydegger A.
Collaborateur(s)
Swiss IBD Cohort Study
ISSN
1473-5687 (Electronic)
ISSN-L
0954-691X
Statut éditorial
Publié
Date de publication
10/2018
Peer-reviewed
Oui
Volume
30
Numéro
10
Pages
1159-1167
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
During the past decade, several new drugs were approved for the treatment of pediatric inflammatory bowel disease (IBD). We aimed to evaluate if and how pharmacologic treatment options for pediatric IBD in Switzerland have changed over time.
Data from the pediatric Swiss IBD Cohort Study, a national prospective cohort study initiated in 2006, were analyzed. Patients were divided into two groups: patients with IBD diagnosis until 2009 (168 patients) and patients with IBD diagnosis in 2010 and after (210 patients). Both groups were analyzed regarding the past and the current therapies as well as need for surgery.
Overall, 378 pediatric patients with IBD were analyzed, of which 51.9% had Crohn's disease (CD) and 48.1% had ulcerative colitis/indeterminate colitis. Median age at diagnosis was 12 years. The majority (65.4%) of the patients with ulcerative colitis experienced pancolitis, whereas 45.4% of patients with CD presented with ileocolonic disease at diagnosis. A decreased use of corticosteroids in pediatric patients with CD can be found after 2010 (P=0.041). Use of 5-aminosalicylic acid for patients with CD was dramatically reduced after the year 2010 (33.5 vs. 67.7% after 6 years of disease). A significant shift toward earlier use of biologicals could be shown after 2010 (P<0.001). However, there was no significant decrease of surgery rate after 5 years of disease.
In the past decade, a significant earlier use of anti-tumor necrosis factor-α agents in pediatric patients with IBD was observed with steroid-sparing effect in patients with CD. However, this change was not associated with reduction of surgery.
Mots-clé
Adolescent, Adrenal Cortex Hormones/therapeutic use, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Biological Products/therapeutic use, Child, Colitis, Ulcerative/drug therapy, Colitis, Ulcerative/surgery, Crohn Disease/drug therapy, Crohn Disease/surgery, Drug Therapy/trends, Female, Humans, Immunosuppressive Agents/therapeutic use, Male, Mesalamine/therapeutic use, Retrospective Studies, Switzerland, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Web of science
Open Access
Oui
Création de la notice
20/07/2018 15:08
Dernière modification de la notice
20/08/2019 12:30
Données d'usage